Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour intraocular pressure-lowering effect of sepetaprost
jRCTs031260350Recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sepetaprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoint: Comparison of diurnal and nocturnal mean intraocular pressure at Weeks 0 and 4. Started Sep 2026; status: recruiting.
02
Drugs
sepetaprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCTs031260350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260350.